Results 161 to 170 of about 21,074 (263)

Five-year follow-up of incretin-based therapy in a patient with KCNJ11-related permanent neonatal diabetes: Achieving insulin discontinuation and sulfonylurea reduction. [PDF]

J Diabetes Investig
Ohkuma T, Aotani R, Sakamoto W, Oshiro A, Ago T.   +4 more
europepmc   +1 more source

Effects of Oral Semaglutide on Dietary Intake and Body Composition in Japanese People With Type 2 Diabetes: A Prospective Observational Study in Clinical Practice

Endocrinology, Diabetes &Metabolism, Volume 9, Issue 5, September 2026.
This prospective observational study evaluated changes in dietary patterns and body composition after 3 months of oral semaglutide treatment in people with Type 2 diabetes. Oral semaglutide was associated with reduced energy intake, salt intake and body fat while preserving handgrip strength.
Mika Sawada, Naoko Nakanishi, Masakazu Aihara, Kanako Ohkuma, Shoko Hamano, Yoshitaka Sakurai, Rie Sekine, Satoshi Usami, Toshimasa Yamauchi, Naoto Kubota   +9 more
wiley   +1 more source

Real-world use of semaglutide for obesity treatment: A cohort study in an integrated health care delivery system. [PDF]

J Manag Care Spec Pharm
Baalmann A, Michel J, Avedissian SN, Pow A, Farris K.   +4 more
europepmc   +1 more source

Tirzepatide and SGLT2 Inhibitors for Heart Failure With Preserved Ejection Fraction and Obesity: Entering a New Cardiometabolic Therapeutic Era

Endocrinology, Diabetes &Metabolism, Volume 9, Issue 5, September 2026.
Tirzepatide and SGLT2 inhibitors act through distinct but complementary mechanisms in obesity‐related HFpEF: tirzepatide targets adiposity, inflammation, and insulin resistance, while SGLT2 inhibitors improve decongestion, myocardial energetics, and cardiac remodeling.
Zakariye Isak Mohamed, Abdinasir Adam Shidane, Abdullahi Mohamud Abdiasis, Mohamed Hassan Hussein, Ayaanle Osman Ibrahim, Anas Ali Abdi, Kowthar Ismail Hashi, Mohamed Abdullahi Mohamud, Ali Jimale Mohamed   +8 more
wiley   +1 more source

Hope or hype? Obesity management medications and real-world obstructive sleep apnea outcomes. [PDF]

Ann Am Thorac Soc
Nokes B, Zou D.
europepmc   +1 more source

Combination Pharmacotherapies for Obesity—Current Evidence and Future Directions

Endocrinology, Diabetes &Metabolism, Volume 9, Issue 5, September 2026.
Combination pharmacotherapy for obesity can enhance weight loss by targeting complementary neuroendocrine and metabolic pathways. Such benefits are largely additive but limited by tolerability, cost and access. This review outlines practical clinical archetypes and a research agenda for safer, more precise and durable combination strategies across ...
A. B. M. Kamrul‐Hasan, Arnav Kalra, Nitin Kapoor, Deep Dutta, Kunal Mahajan, Robin Maskey, Syed Abbas Raza   +6 more
wiley   +1 more source

Reframing obesity-related HFpEF as a multiorgan syndrome: incretin-based therapies and imaging endpoints. [PDF]

Heart Fail Rev
Mahmod M, Dennis A, Lian J, Langford C, Rahimi K, Wamil M.   +5 more
europepmc   +1 more source

The broadening incretin concept

Gastroenterology, 1980
openaire   +2 more sources

Incretin mimetic [PDF]

, 2020
openaire   +1 more source

Qualitative and Quantitative Health‐Related Quality‐of‐Life Outcomes From an 8‐year Follow‐Up After Gastric Bypass Surgery in People With Type 2 Diabetes

Endocrinology, Diabetes &Metabolism, Volume 9, Issue 5, September 2026.
Quality of life after gastric bypass is a multidimensional, evolving process influenced by changing health, life circumstances and psychosocial factors over time, including: physical functioning, psychological well‐being, body adaptation, social supports and life events.
Giovanni Fanni, Petros Katsogiannos, Magnus Sundbom, Janeth Leksell, Eva Randell   +4 more
wiley   +1 more source